# A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

Study · id `cardio:ct-nct07477704` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07477704](<https://clinicaltrials.gov/study/NCT07477704>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07477704

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 438 participants.

## Technical summary

Registry record NCT07477704. Randomized; no masking; primary purpose treatment. Start 2026-06-17 (actual); primary completion 2026-12-29 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 438 participants (enrolled count; ClinicalTrials.gov record NCT07477704, source copy `cardio:ctgov-nct07477704-2026-10-15`, retrieved 2026-10-31)
- Started: 2026-06-17 (actual) (ClinicalTrials.gov record NCT07477704, source copy `cardio:ctgov-nct07477704-2026-10-15`, retrieved 2026-10-31)
- Primary completion: 2026-12-29 (anticipated) (ClinicalTrials.gov record NCT07477704, source copy `cardio:ctgov-nct07477704-2026-10-15`, retrieved 2026-10-31)
- Completion: 2027-02-23 (anticipated) (ClinicalTrials.gov record NCT07477704, source copy `cardio:ctgov-nct07477704-2026-10-15`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT07477704, source copy `cardio:ctgov-nct07477704-2026-10-15`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07477704-2026-10-15`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- Acronym: ASCEND-QW
- Condition: Hypercholesterolemia
- Intervention (Drug): Alirocumab
- Lead sponsor: Regeneron Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Alirocumab (`cardio:alirocumab`)
- Registry lists this organization as the lead sponsor: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

## Provenance

Content hash: 52e4b860ddd5ac9da5fd74497e78cfade5f034204de6b3affc2975406834e341
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
